Diabetes drug found no better than placebo at treating NAFLD
A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: Clinical Trials | Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Januvia | Liver | Liver Disease | Merck | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pharmaceuticals | Study | Urology & Nephrology